[go: up one dir, main page]

MX2015008021A - Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. - Google Patents

Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.

Info

Publication number
MX2015008021A
MX2015008021A MX2015008021A MX2015008021A MX2015008021A MX 2015008021 A MX2015008021 A MX 2015008021A MX 2015008021 A MX2015008021 A MX 2015008021A MX 2015008021 A MX2015008021 A MX 2015008021A MX 2015008021 A MX2015008021 A MX 2015008021A
Authority
MX
Mexico
Prior art keywords
transdermal delivery
methods
hormones
compositions
medicinal agents
Prior art date
Application number
MX2015008021A
Other languages
English (en)
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Edward Kisak
John Newsam
Jianye Wen
Jutaro Shudo
Amit Jain
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Publication of MX2015008021A publication Critical patent/MX2015008021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona sistemas de administración transdérmica, paquetes médicos y métodos para el uso de los sistemas y paquetes de administración transdérmica para aplicaciones médicas, tal como la administración de agentes anticonceptivos para el control de la fertilidad.
MX2015008021A 2012-12-21 2013-12-20 Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. MX2015008021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740879P 2012-12-21 2012-12-21
PCT/US2013/076948 WO2014100599A1 (en) 2012-12-21 2013-12-20 Compositions and methods for transdermal delivery of hormones and other medicinal agents

Publications (1)

Publication Number Publication Date
MX2015008021A true MX2015008021A (es) 2016-03-04

Family

ID=49943582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008021A MX2015008021A (es) 2012-12-21 2013-12-20 Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.

Country Status (11)

Country Link
US (2) US9144553B2 (es)
EP (1) EP2934497B1 (es)
JP (1) JP6336476B2 (es)
CN (1) CN104936582B (es)
AU (1) AU2013361106B2 (es)
CA (1) CA2894696A1 (es)
EA (1) EA030797B1 (es)
ES (1) ES2613721T3 (es)
MX (1) MX2015008021A (es)
TW (1) TW201431572A (es)
WO (1) WO2014100599A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894696A1 (en) 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
TW201431554A (zh) 2012-12-28 2014-08-16 Noven Pharma 左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及乙烯雌二醇之經皮藥物遞送系統
US20160199317A1 (en) * 2013-08-30 2016-07-14 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US9603967B2 (en) * 2015-05-08 2017-03-28 Vivex Biomedical, Inc. Placental tissue assembly
EP3297634A1 (en) * 2015-05-18 2018-03-28 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
WO2017004507A1 (en) * 2015-07-02 2017-01-05 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
JP2018537503A (ja) * 2015-12-16 2018-12-20 アケリオス セラピューティクス，インコーポレーテッド 末梢神経障害を治療するための方法及び組成物
US10716754B2 (en) 2016-03-28 2020-07-21 Tioga Research, Inc. Topical formulation
WO2018009565A1 (en) * 2016-07-06 2018-01-11 Agile Therapeutics, Inc. Transdermal packaging membranes
CA3207668A1 (en) 2017-04-30 2018-11-08 Dmk Pharmaceuticals Corporation An opioid for use to reduce and/or treat drug addiction

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296230A (en) 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
ATE453374T1 (de) * 1999-11-24 2010-01-15 Agile Therapeutics Inc Verbessertes transdermales verabreichungssystem zur empfängnisverhütung und verfahren
EP1507538A1 (en) 2002-05-30 2005-02-23 Watson Pharmaceuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
EA009623B1 (ru) 2003-04-30 2008-02-28 Пэдью Фарма Л.П. Устойчивая к манипуляциям дозировочная форма для трансдермального введения
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
US7468470B2 (en) 2004-03-26 2008-12-23 Schering Ag Medicinal patch that leaves less adhesive residue when removed
US20060121102A1 (en) 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
US7795309B2 (en) 2006-03-06 2010-09-14 Fqubed Inc. Topical formulation including diclofenac, or a pharmaceutically acceptable salt thereof
CN101588791A (zh) 2006-10-17 2009-11-25 纽沃研究公司 双氯芬酸凝胶
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
WO2009009649A1 (en) 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
US20090098191A1 (en) 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
KR101514342B1 (ko) * 2007-11-22 2015-04-22 가부시키가이샤 메드렉스 지방산계 이온 액체를 유효성분으로 하는 외용제 조성물
US20090297590A1 (en) * 2008-05-30 2009-12-03 Masahiro Yamaji Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US20110288123A1 (en) 2008-11-06 2011-11-24 Nuvo Research Inc. Formulations for the treatment of acute herpes zoster pain
WO2011014850A2 (en) 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations
US20120214874A1 (en) 2009-08-26 2012-08-23 Nuvo Research Inc. Pharmaceutical formulations and methods of use
WO2011041609A2 (en) 2009-09-30 2011-04-07 Nuvo Research Inc. Topical formulations
WO2011044540A1 (en) 2009-10-09 2011-04-14 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
WO2011060195A2 (en) 2009-11-11 2011-05-19 Nuvo Research Inc. Topical eutectic formulation
CN102711835B (zh) 2009-11-27 2014-12-10 努沃研究股份有限公司 局部布洛芬制剂
AU2010336441B2 (en) 2009-12-23 2015-02-05 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
WO2011088072A2 (en) 2010-01-14 2011-07-21 Agile Therapeutics, Inc. Dermal delivery device
EP2544662B1 (en) 2010-03-10 2020-05-20 Nuvo Pharmaceuticals Inc. Foamable formulation
EA023786B1 (ru) 2010-04-30 2016-07-29 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальные композиции на основе пропиниламиноиндана
WO2011149645A1 (en) 2010-05-28 2011-12-01 Nuvo Research Inc. Topical etoricoxib formulation
AU2011331511C1 (en) * 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
CA2894696A1 (en) 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents

Also Published As

Publication number Publication date
CA2894696A1 (en) 2014-06-26
CN104936582B (zh) 2018-12-21
EP2934497A1 (en) 2015-10-28
ES2613721T3 (es) 2017-05-25
CN104936582A (zh) 2015-09-23
AU2013361106B2 (en) 2017-06-01
US9579296B2 (en) 2017-02-28
AU2013361106A1 (en) 2015-07-02
WO2014100599A1 (en) 2014-06-26
JP6336476B2 (ja) 2018-06-06
TW201431572A (zh) 2014-08-16
EA201591196A1 (ru) 2015-12-30
EP2934497B1 (en) 2016-11-23
EA030797B1 (ru) 2018-09-28
JP2016503802A (ja) 2016-02-08
US20140178459A1 (en) 2014-06-26
US9144553B2 (en) 2015-09-29
US20160051487A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2019005833A (es) Administracion transdermica de agentes grandes.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2014008693A (es) Administracion transdermica de hormonas.
MX2015016603A (es) Composiciones de corticosteroides.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process